Journal Title
Title of Journal: Cancer Immunol Immunother
|
Abbravation: Cancer Immunology, Immunotherapy
|
Publisher
Springer-Verlag
|
|
|
|
|
|
Authors: Riguel J Inaoka Achim A Jungbluth Sacha Gnjatic Erika Ritter Nicole C Hanson Denise Frosina Jodie Tassello Leina Y Etto Adriana B Bortoluzzo Antonio C Alves Gisele W B Colleoni
Publish Date: 2012/05/26
Volume: 61, Issue: 12, Pages: 2207-2214
Abstract
Based on their tumorassociated expression pattern cancer/testis antigens CTAs are considered potential targets for cancer immunotherapy We aim to evaluate the expression of CTAs in nonHodgkin’s lymphoma NHL samples and the ability of these patients to elicit spontaneous humoral immune response against CTAsExpression of MAGEA family CT7/MAGEC1 CT10/MAGEC2 GAGE and NYESO1 was analyzed by immunohistochemistry in a tissue microarray generated from 106 NHL archival cases The humoral response against 19 CTAs was tested in 97 untreated NHL serum samples using ELISA technique113 of NHL tumor samples expressed at least 1 CTA MAGEA family 66 GAGE 57 and NYESO147 were the most frequently expressed antigens We found no statistically significant correlation between CTA positivity and clinical parameters such as NHL histological subtype Ann Arbor stage international prognostic index score response to treatment and overall survival Humoral response against at least 1 CTA was observed in 165 of NHL serum samples However overall seroreactivity was low and strong titers 11000 were observed in only two diffuse large Bcell lymphomas patients against CT45Our findings are in agreement with most of published studies in this field to date and suggest an overall low expression of CTAs in NHL patients However as many new CTAs have been described recently and some of them are found to be highly expressed in NHL cell lines and tumor samples further studies exploring the expression of different panels of CTAs are needed to evaluate their role as candidates for immunotherapy in NHL patients
Keywords:
.
|
Other Papers In This Journal:
- Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy
- Second International Symposium on Cancer Biology (ISCB), November 14–16, 2011, at the National Institute of Immunology, New Delhi, India
- Saccharomyces cerevisiae , the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice
- Higher numbers of T-bet + intratumoral lymphoid cells correlate with better survival in gastric cancer
- Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E 2 results in high interleukin-12 production and cell migration
- Increase in CD14 + HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells
- Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma
- Epigenetic regulation of immune escape genes in cancer
- The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis
- Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses
- Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle
- −509C>T polymorphism in the TGF-β1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection
- Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004
- Heterogeneity of CD8 + tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies
- Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma
- Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
- Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells
- Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms
- H 2 O 2 production within tumor microenvironment inversely correlated with infiltration of CD56 dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction
- Lenalidomide enhances anti-myeloma cellular immunity
- Epidemiology: allergy history, IgE, and cancer
- Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
- Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
- Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
- Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors
- Chordoma and chondrosarcoma gene profile: implications for immunotherapy
- Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma
- Extracellular adenosine metabolism in immune cells in melanoma
- Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity
- Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
- Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies
- Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function
- Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis
|